Business
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 SOUTH SAN
About this update from Quince Therapeutics, Inc.
[{"type":"text","content":"\nStrong cash position expected to provide sufficient operating runway into 2026;\nPhase 3 topline results expected in the fourth quarter of 2025\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nQuince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the second quarter ended June 30, 2024.\n\n\nDirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “We achieved a major clinical milestone during the second quarter of 2024 with the first patient enrolled in our pivotal Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T). As of today, we have enrolled seven patients with A-T across clinical sites in the U.S., U.K., and European Union. We are encouraged by this strong start and expect NEAT site activation and patient screening activities to accelerate over the next quarter.”\n\n\nPivotal Phase 3 NEAT Clinical Trial\n\n\n\nDosed the first patient in the company’s Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T; IEDAT-04-2022/NCT06193200) clinical trial to evaluate the neurological effects of EryDex in patients with A-T in June 2024.\n\n\n\n\nEnrolled seven patients with A-T in the NEAT clinical trial to date. Quince plans to enroll approximately 86 patients with A-T ages six to nine years old (primary analysis population) and approximately 20 patients with A-T ages 10 years or older.\n\n\n\n\nNEAT is an international, multi-center, randomized, double-blind, placebo-controlled study to evaluate the neurological effects of the company’s lead asset, EryDex (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells), in patients with A-T.\n\n\n\n\nPivotal Phase 3 NEAT clinical trial is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA).\n\n\n\n\nParticipants will be randomized (1:1) between EryDex or placebo and treatment will consist of six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last visit completion in a rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo.\n\n\n\n\...